A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer

Breast Cancer Research and Treatment, 05/08/2012

The tipifarnib–capecitabine combination is not more effective than capecitabine alone in metastatic breast cancer (MBC) patients who were previously treated with an anthracycline and taxane therapy.

Print Article Summary